MedDataX Logo

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

NCT00985088 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1343

Last updated 2017-12-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to characterize the safety and immunogenicity of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older.

This protocol posting has been updated for sections impacted by the Protocol amendment 1, Sept 2009.

Conditions

  • Influenza

Interventions

BIOLOGICAL

GSK2340274A

one or two intramuscular injections

BIOLOGICAL

GSK2340273A

one or two intramuscular injections

BIOLOGICAL

Saline placebo

One injection

Sponsors & Collaborators

  • GlaxoSmithKline

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-11
Primary Completion
2009-11-09
Completion
2010-12-16

Countries

  • United States
  • Canada

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00985088 on ClinicalTrials.gov